Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1928 2
1931 1
1961 1
1963 1
1966 1
1967 1
1968 1
1969 1
1970 1
1971 3
1972 1
1973 1
1975 2
1976 2
1977 4
1978 8
1979 6
1980 6
1981 14
1982 15
1983 17
1984 21
1985 12
1986 6
1987 8
1988 10
1989 17
1990 12
1991 10
1992 17
1993 9
1994 18
1995 17
1996 28
1997 15
1998 21
1999 8
2000 13
2001 10
2002 13
2003 12
2004 18
2005 19
2006 20
2007 17
2008 18
2009 25
2010 23
2011 41
2012 25
2013 30
2014 42
2015 36
2016 43
2017 48
2018 52
2019 45
2020 46
2021 60
2022 49
2023 32
2024 31

Text availability

Article attribute

Article type

Publication date

Search Results

993 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. DiSilvestro P, et al. Among authors: friedlander m. J Clin Oncol. 2023 Jan 20;41(3):609-617. doi: 10.1200/JCO.22.01549. Epub 2022 Sep 9. J Clin Oncol. 2023. PMID: 36082969 Free PMC article. Clinical Trial.
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Berek JS, et al. Among authors: friedlander m. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61-85. doi: 10.1002/ijgo.13878. Int J Gynaecol Obstet. 2021. PMID: 34669199 Free PMC article. Review.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Poveda A, et al. Among authors: friedlander m. Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18. Lancet Oncol. 2021. PMID: 33743851 Clinical Trial.
The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.
Garsed DW, Pandey A, Fereday S, Kennedy CJ, Takahashi K, Alsop K, Hamilton PT, Hendley J, Chiew YE, Traficante N, Provan P, Ariyaratne D, Au-Yeung G, Bateman NW, Bowes L, Brand A, Christie EL, Cunningham JM, Friedlander M, Grout B, Harnett P, Hung J, McCauley B, McNally O, Piskorz AM, Saner FAM, Vierkant RA, Wang C, Winham SJ, Pharoah PDP, Brenton JD, Conrads TP, Maxwell GL, Ramus SJ, Pearce CL, Pike MC, Nelson BH, Goode EL, DeFazio A, Bowtell DDL. Garsed DW, et al. Among authors: friedlander m. Nat Genet. 2022 Dec;54(12):1853-1864. doi: 10.1038/s41588-022-01230-9. Epub 2022 Dec 1. Nat Genet. 2022. PMID: 36456881 Free PMC article.
Reply.
Tzaridis S, Friedlander M. Tzaridis S, et al. Among authors: friedlander m. Retina. 2022 Mar 1;42(3):e23. doi: 10.1097/IAE.0000000000003393. Retina. 2022. PMID: 34954780 No abstract available.
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Ledermann J, et al. Among authors: friedlander m. N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27. N Engl J Med. 2012. PMID: 22452356 Free article. Clinical Trial.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ. Ganz PA, et al. Among authors: friedlander m. J Clin Oncol. 2024 Apr 10;42(11):1288-1300. doi: 10.1200/JCO.23.01214. Epub 2024 Feb 1. J Clin Oncol. 2024. PMID: 38301187 Free PMC article. Clinical Trial.
993 results